S P Robinson1,2, A Boumendil2, H Finel2, H Schouten3, G Ehninger4, J Maertens5, C Crawley6, A Rambaldi7, N Russell8, W Anders9, D Blaise10, I Yakoub-Agha11, A Ganser12, L Castagna13, L Volin14, J-Y Cahn15, S Montoto2,16, P Dreger2,17. 1. BMT Unit, University Hospital Bristol NHS Foundation Trust, Bristol, UK. 2. Lymphoma Working Party EBMT, Paris, France. 3. Department of Haematology, University Hospital, Maastricht, The Netherlands. 4. Department of Haematology, Universitaetsklinikum, Dresden, Germany. 5. Department of Haematology, University Hospital Gasthuisberg, Leuven, Belgium. 6. Department of Haematology, Addenbrookes Hospital, Cambridge, UK. 7. Haematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. 8. Department of Haematology, City Hospital, Nottingham, UK. 9. Department of Haematology, University Hospital, Umea, Sweden. 10. Department of Haematology, Institut Paoli Calmettes, Marseille. 11. Department of Haematology, Hôpital Claude Huriez, Lille, France. 12. Department of Haematology, Medical School, Hannover, Germany. 13. Department of Haematology, Istituto Clinico Humanitas, Milano, Italy. 14. HUH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland. 15. Haematology, Clinique Universitaire d'Hématologie CHU Grenoble UMR 38043, Grenoble Cedex 09, France. 16. Department of Haematology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK. 17. Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
Abstract
BACKGROUND: Patients with follicular lymphoma (FL) relapsing after an autologous transplant (autoSCT) may be treated with a variety of therapies, including a reduced intensity allogeneic transplant (RICalloSCT). We conducted a retrospective analysis of a large cohort of patients undergoing RICalloSCT for FL in this setting. PATIENTS AND METHODS: A total of 183 patients, median age 45 years (range 21-69), had undergone an autoSCT at a median of 30 months before the RICalloSCT. Before the RICalloSCT, they had received a median of four lines (range 3-10) of therapy and 81% of patients had chemosensitive disease and 16% had chemoresistant disease. Grafts were donated from sibling (47%) or unrelated donors (53%). RESULTS: With a median follow-up of 59 months, the non-relapse mortality (NRM) was 27% at 2 years. The median remission duration post-autoSCT and RICalloSCT was 14 and 43 months, respectively. The 5-year relapse/progression rate, progression-free survival and overall survival were 16%, 48% and 51%, respectively, and were associated with age and disease status at RICalloSCT. CONCLUSION: These data suggest that an RICalloSCT is an effective salvage strategy in patients with FL recurring after a prior autoSCT and might overcome the poor prognostic impact of early relapse after autoSCT.
BACKGROUND:Patients with follicular lymphoma (FL) relapsing after an autologous transplant (autoSCT) may be treated with a variety of therapies, including a reduced intensity allogeneic transplant (RICalloSCT). We conducted a retrospective analysis of a large cohort of patients undergoing RICalloSCT for FL in this setting. PATIENTS AND METHODS: A total of 183 patients, median age 45 years (range 21-69), had undergone an autoSCT at a median of 30 months before the RICalloSCT. Before the RICalloSCT, they had received a median of four lines (range 3-10) of therapy and 81% of patients had chemosensitive disease and 16% had chemoresistant disease. Grafts were donated from sibling (47%) or unrelated donors (53%). RESULTS: With a median follow-up of 59 months, the non-relapse mortality (NRM) was 27% at 2 years. The median remission duration post-autoSCT and RICalloSCT was 14 and 43 months, respectively. The 5-year relapse/progression rate, progression-free survival and overall survival were 16%, 48% and 51%, respectively, and were associated with age and disease status at RICalloSCT. CONCLUSION: These data suggest that an RICalloSCT is an effective salvage strategy in patients with FL recurring after a prior autoSCT and might overcome the poor prognostic impact of early relapse after autoSCT.
Authors: Anna Sureda; Mei-Jie Zhang; Peter Dreger; Jeanette Carreras; Timothy Fenske; Herve Finel; Harry Schouten; Silvia Montoto; Stephen Robinson; Sonali M Smith; Ariane Boumedil; Mehdi Hamadani; Marcelo C Pasquini Journal: Cancer Date: 2018-02-09 Impact factor: 6.860
Authors: Nirav N Shah; Kwang Woo Ahn; Carlos Litovich; Timothy S Fenske; Sairah Ahmed; Minoo Battiwalla; Nelli Bejanyan; Parastoo B Dahi; Javier Bolaños-Meade; Andy I Chen; Stefan O Ciurea; Veronika Bachanova; Zachariah DeFilipp; Narendranath Epperla; Nosha Farhadfar; Alex F Herrera; Bradley M Haverkos; Leona Holmberg; Nasheed M Hossain; Mohamed A Kharfan-Dabaja; Vaishalee P Kenkre; Hillard M Lazarus; Hemant S Murthy; Taiga Nishihori; Andrew R Rezvani; Anita D'Souza; Bipin N Savani; Matthew L Ulrickson; Edmund K Waller; Anna Sureda; Sonali M Smith; Mehdi Hamadani Journal: Blood Adv Date: 2018-04-24
Authors: Sonali M Smith; James Godfrey; Kwang Woo Ahn; Alyssa DiGilio; Sairah Ahmed; Vaibhav Agrawal; Veronika Bachanova; Ulrike Bacher; Asad Bashey; Javier Bolaños-Meade; Mitchell Cairo; Andy Chen; Saurabh Chhabra; Edward Copelan; Parastoo B Dahi; Mahmoud Aljurf; Umar Farooq; Siddhartha Ganguly; Mark Hertzberg; Leona Holmberg; David Inwards; Abraham S Kanate; Reem Karmali; Vaishalee P Kenkre; Mohamed A Kharfan-Dabaja; Andreas Klein; Hillard M Lazarus; Matthew Mei; Alberto Mussetti; Taiga Nishihori; Praveen Ramakrishnan Geethakumari; Ayman Saad; Bipin N Savani; Harry C Schouten; Nirav Shah; Alvaro Urbano-Ispizua; Ravi Vij; Julie Vose; Anna Sureda; Mehdi Hamadani Journal: Cancer Date: 2018-04-12 Impact factor: 6.860